Home › Compare › PTMEY vs ABBV
PTMEY yields 171.23% · ABBV yields 3.06%● Live data
📍 ABBV pulled ahead of the other in Year 9
Combined, PTMEY + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of PTMEY + ABBV for your $10,000?
PT. Media Nusantara Citra Tbk operates as a media company in Indonesia. It operates through Television, Radio, Print Media, Content, and Advertising Agency segments. The company owns and operates national free-to-air televisions (TV), such as RCTI TV station that offers a range of programs, including drama series, box office movies, sports events, talent search shows, reality and music shows, anniversary and awards programs, and infotainment programs; MNCTV, which offers family drama series, animation, sports programs, and various shows; GTV that focuses on animation, variety shows, reality shows, game shows, and talent search programs; and iNews TV, which focuses on sports and other factual programs, as well as offers content library and talent management services. It also operates StarPro, which provides an infotainment channel on pay-TV platforms; Okezone.com, IDXChannel.com, and Sindonews.com news portals that serve Indonesian readers; RCTI+, an entertainment app; iNews.id, a news portal comprising national and regional news; Celebrities.id, a portal around celebrities and lifestyle; sportstars.id; StarHits, a digital creator network; ROOV, a radio streaming website; and eTV Mall, which allows TV viewers to purchase e-vouchers from advertisements on a TV program. The company was founded in 1987 and is headquartered in Jakarta Pusat, Indonesia. PT. Media Nusantara Citra Tbk is a subsidiary of PT Global Mediacom Tbk.
Full PTMEY Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.